Cargando…
Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care–Insured Women, New York State, 2012–2014
INTRODUCTION: In 2010, national guidelines recommended that women with nonmetastatic, hormone receptor–positive breast cancer take adjuvant hormone therapy for 5 years. As results from randomized clinical trials became available, guidelines were revised in 2014 to recommend 10 years of therapy. Desp...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008863/ https://www.ncbi.nlm.nih.gov/pubmed/27584876 http://dx.doi.org/10.5888/pcd13.160185 |
_version_ | 1782451453848190976 |
---|---|
author | Wagner, Victoria L. Jing, Wei Boscoe, Francis P. Schymura, Maria J. Roohan, Patrick J. Gesten, Foster C. |
author_facet | Wagner, Victoria L. Jing, Wei Boscoe, Francis P. Schymura, Maria J. Roohan, Patrick J. Gesten, Foster C. |
author_sort | Wagner, Victoria L. |
collection | PubMed |
description | INTRODUCTION: In 2010, national guidelines recommended that women with nonmetastatic, hormone receptor–positive breast cancer take adjuvant hormone therapy for 5 years. As results from randomized clinical trials became available, guidelines were revised in 2014 to recommend 10 years of therapy. Despite evidence of its efficacy, low initiation rates have been documented among women insured by New York State Medicaid. This article describes a coordinated quality improvement pilot conducted by a state department of health and Medicaid managed care plans to engage women in guideline-concordant adjuvant hormone therapy. METHODS: Women enrolled in Medicaid managed care with nonmetastatic, hormone receptor–positive breast cancer and who had surgery from May 1, 2012, through November 30, 2012, were identified using linked Medicaid and Cancer Registry data. Adjuvant hormone therapy status was determined from Medicaid pharmacy data. Contact information for nonadherent women was supplied to health plan care managers who conducted outreach activities. Adjuvant hormone therapy status in the 6 months following outreach was evaluated. RESULTS: In the 6 months postoutreach, 61% of women in the contacted group filled at least 1 prescription, compared with 52% in the noncontacted group. Among those with at least 1 filled prescription, 50% of the contacted group were adherent, compared with 25% in the noncontacted group. CONCLUSION: This pilot suggests outreach conducted by health plan care managers, facilitated by linked Medicaid and Cancer Registry data, is an effective method to improve adjuvant hormone therapy initiation and adherence rates in Medicaid managed care–insured women. |
format | Online Article Text |
id | pubmed-5008863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-50088632016-09-14 Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care–Insured Women, New York State, 2012–2014 Wagner, Victoria L. Jing, Wei Boscoe, Francis P. Schymura, Maria J. Roohan, Patrick J. Gesten, Foster C. Prev Chronic Dis Original Research INTRODUCTION: In 2010, national guidelines recommended that women with nonmetastatic, hormone receptor–positive breast cancer take adjuvant hormone therapy for 5 years. As results from randomized clinical trials became available, guidelines were revised in 2014 to recommend 10 years of therapy. Despite evidence of its efficacy, low initiation rates have been documented among women insured by New York State Medicaid. This article describes a coordinated quality improvement pilot conducted by a state department of health and Medicaid managed care plans to engage women in guideline-concordant adjuvant hormone therapy. METHODS: Women enrolled in Medicaid managed care with nonmetastatic, hormone receptor–positive breast cancer and who had surgery from May 1, 2012, through November 30, 2012, were identified using linked Medicaid and Cancer Registry data. Adjuvant hormone therapy status was determined from Medicaid pharmacy data. Contact information for nonadherent women was supplied to health plan care managers who conducted outreach activities. Adjuvant hormone therapy status in the 6 months following outreach was evaluated. RESULTS: In the 6 months postoutreach, 61% of women in the contacted group filled at least 1 prescription, compared with 52% in the noncontacted group. Among those with at least 1 filled prescription, 50% of the contacted group were adherent, compared with 25% in the noncontacted group. CONCLUSION: This pilot suggests outreach conducted by health plan care managers, facilitated by linked Medicaid and Cancer Registry data, is an effective method to improve adjuvant hormone therapy initiation and adherence rates in Medicaid managed care–insured women. Centers for Disease Control and Prevention 2016-09-01 /pmc/articles/PMC5008863/ /pubmed/27584876 http://dx.doi.org/10.5888/pcd13.160185 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Original Research Wagner, Victoria L. Jing, Wei Boscoe, Francis P. Schymura, Maria J. Roohan, Patrick J. Gesten, Foster C. Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care–Insured Women, New York State, 2012–2014 |
title | Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care–Insured Women, New York State, 2012–2014 |
title_full | Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care–Insured Women, New York State, 2012–2014 |
title_fullStr | Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care–Insured Women, New York State, 2012–2014 |
title_full_unstemmed | Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care–Insured Women, New York State, 2012–2014 |
title_short | Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care–Insured Women, New York State, 2012–2014 |
title_sort | improving adjuvant hormone therapy use in medicaid managed care–insured women, new york state, 2012–2014 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008863/ https://www.ncbi.nlm.nih.gov/pubmed/27584876 http://dx.doi.org/10.5888/pcd13.160185 |
work_keys_str_mv | AT wagnervictorial improvingadjuvanthormonetherapyuseinmedicaidmanagedcareinsuredwomennewyorkstate20122014 AT jingwei improvingadjuvanthormonetherapyuseinmedicaidmanagedcareinsuredwomennewyorkstate20122014 AT boscoefrancisp improvingadjuvanthormonetherapyuseinmedicaidmanagedcareinsuredwomennewyorkstate20122014 AT schymuramariaj improvingadjuvanthormonetherapyuseinmedicaidmanagedcareinsuredwomennewyorkstate20122014 AT roohanpatrickj improvingadjuvanthormonetherapyuseinmedicaidmanagedcareinsuredwomennewyorkstate20122014 AT gestenfosterc improvingadjuvanthormonetherapyuseinmedicaidmanagedcareinsuredwomennewyorkstate20122014 |